Merck & Co. Inc. (MRK)

83.65
1.60 1.90
NYSE : Health Technology
Prev Close 85.24
Open 85.18
Day Low/High 83.09 / 85.20
52 Wk Low/High 59.80 / 86.50
Volume 5.92M
Avg Volume 10.09M
Exchange NYSE
Shares Outstanding 2.57B
Market Cap 220.16B
EPS 2.30
P/E Ratio 49.72
Div & Yield 2.20 (2.44%)

Latest News

Here's Why I'm Sticking With Merck

Here's Why I'm Sticking With Merck

The charts are saying MRK is ready to rise.

Merck Hosts 2019 Investor Day Outlining Business Momentum, Strong Expected Growth And Focus On Innovative Research And Development

Merck Hosts 2019 Investor Day Outlining Business Momentum, Strong Expected Growth And Focus On Innovative Research And Development

At a meeting with the investment community today, Merck (NYSE: MRK), known as MSD outside the United States and Canada, will outline how its science-led strategy and broad pipeline of promising transformative therapies and vaccines will position the...

AstraZeneca And Merck's LYNPARZA® (olaparib) Approved In Japan As First-Line Maintenance Therapy In Patients With BRCA-Mutated Advanced Ovarian Cancer

AstraZeneca And Merck's LYNPARZA® (olaparib) Approved In Japan As First-Line Maintenance Therapy In Patients With BRCA-Mutated Advanced Ovarian Cancer

AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Japan's Pharmaceuticals and Medical Devices Agency (PMDA) has approved LYNPARZA as a maintenance treatment after first-line chemotherapy in patients...

LYNPARZA® (olaparib) Approved In The EU For Use As First-Line Maintenance Therapy In Patients With BRCA-Mutated Advanced Ovarian Cancer

LYNPARZA® (olaparib) Approved In The EU For Use As First-Line Maintenance Therapy In Patients With BRCA-Mutated Advanced Ovarian Cancer

AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the European Commission has approved LYNPARZA as monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV)...

New Targets for Merck Stock as Charts Point Higher

New Targets for Merck Stock as Charts Point Higher

Investors and traders should approach MRK from the long side.

Market Outlook: Cramer's 'Mad Money' Recap (Friday 6/14/19)

Market Outlook: Cramer's 'Mad Money' Recap (Friday 6/14/19)

Jim Cramer's got the low-down on IPOs, the Fed, trade and more. Here's your game plan for next week's action.

How to Invest in Stocks: 14 Keys to Remember

How to Invest in Stocks: 14 Keys to Remember

Larry Swedroe lays out the fundamental truths of investing -- for beginners.

IBM, KPMG, Merck And Walmart To Collaborate As Part Of FDA's Program To Evaluate The Use Of Blockchain To Protect Pharmaceutical Product Integrity

IBM, KPMG, Merck And Walmart To Collaborate As Part Of FDA's Program To Evaluate The Use Of Blockchain To Protect Pharmaceutical Product Integrity

The FDA pilot program explores innovative and emerging approaches for the tracing and verification of prescription products

The 3 Things Jim Cramer Watches For When a Company Announces M&A Plans

The 3 Things Jim Cramer Watches For When a Company Announces M&A Plans

Jim Cramer weighs in on what he's watching when a company announces M&A plans.

FDA Approves Two New Indications For Merck's KEYTRUDA® (pembrolizumab)

FDA Approves Two New Indications For Merck's KEYTRUDA® (pembrolizumab)

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.

Here's How I'm Playing Salesforce.com Stock Now

Here's How I'm Playing Salesforce.com Stock Now

I am no longer as eager to sell these shares as when I discussed this merger pre-opening.

Merck to Buy Tilos Therapeutics for Up to $773 Million

Merck to Buy Tilos Therapeutics for Up to $773 Million

Merck will buy Tilos Therapeutics, a privately held biopharmaceutical company, for up to $773 million.

Jim Cramer: What Merger Mania and a Trump Phone Call Mean for the Markets - LIVE

Jim Cramer: What Merger Mania and a Trump Phone Call Mean for the Markets - LIVE

Here's what Jim Cramer's watching in the markets, Raytheon and United Technology's merger and Salesforce and Merck's acquisitions.

Merck To Acquire Tilos Therapeutics

Merck To Acquire Tilos Therapeutics

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that it has entered into a definitive agreement to acquire Tilos Therapeutics, a privately held biopharmaceutical company developing therapeutics targeting the latent...

FDA Approves Merck's ZERBAXA® (ceftolozane And Tazobactam) 3g Dose For The Treatment Of Adults With Hospital-Acquired And Ventilator-Associated Bacterial Pneumonia (HABP/VABP)

FDA Approves Merck's ZERBAXA® (ceftolozane And Tazobactam) 3g Dose For The Treatment Of Adults With Hospital-Acquired And Ventilator-Associated Bacterial Pneumonia (HABP/VABP)

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.

Kaplan-Meier Estimates Of PFS By Blinded, Independent Central Review (Graphic: Business Wire)

Kaplan-Meier Estimates Of PFS By Blinded, Independent Central Review (Graphic: Business Wire)

AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced detailed results from the Phase 3 POLO trial evaluating LYNPARZA tablets as a first-line maintenance monotherapy for patients with germline BRCA-mutated...

Five-Year Survival Data For Merck's KEYTRUDA® (pembrolizumab) In Advanced Non-Small Cell Lung Cancer (NSCLC) From First KEYNOTE Trial At 2019 ASCO Annual Meeting

Five-Year Survival Data For Merck's KEYTRUDA® (pembrolizumab) In Advanced Non-Small Cell Lung Cancer (NSCLC) From First KEYNOTE Trial At 2019 ASCO Annual Meeting

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of five-year efficacy and safety data for KEYTRUDA, Merck's anti-PD-1 therapy, as monotherapy in patients with advanced non-small cell lung cancer...

Merck's KEYTRUDA® (pembrolizumab) Demonstrates Improved Overall Survival As First-Line Treatment Of Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma At Final Analysis Of Pivotal Phase 3 KEYNOTE-048 Trial

Merck's KEYTRUDA® (pembrolizumab) Demonstrates Improved Overall Survival As First-Line Treatment Of Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma At Final Analysis Of Pivotal Phase 3 KEYNOTE-048 Trial

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of the final analysis of the pivotal Phase 3 KEYNOTE-048 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, as monotherapy and in combination with...

Merck Announces Third-Quarter 2019 Dividend

Merck Announces Third-Quarter 2019 Dividend

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has declared a quarterly dividend of $0.

The Nasdaq A/D Line Peaked Months Ago: Danger Will Robinson

The Nasdaq A/D Line Peaked Months Ago: Danger Will Robinson

'It is not a healthy market when the generals are still going up and the troops are in retreat.'

Merck Foundation Announces Grant To American Cancer Society To Improve Access To Cancer Care In Resource-Limited Settings

Merck Foundation Announces Grant To American Cancer Society To Improve Access To Cancer Care In Resource-Limited Settings

The Merck Foundation (the Foundation) and the American Cancer Society (ACS) announced today that the Foundation awarded a $1.

Stocks Finish Higher, Tech Shares Rebound as U.S. Eases Huawei Restrictions

Stocks Finish Higher, Tech Shares Rebound as U.S. Eases Huawei Restrictions

Stocks finish higher Tuesday as the Commerce Department eases restrictions on China's Huawei.

Merck to Acquire Peloton Therapeutics for About $1B in Cash

Merck to Acquire Peloton Therapeutics for About $1B in Cash

Merck agrees to buy privately held Peloton Therapeutics for $1 billion in cash, giving it access to Peloton's molecular therapy treatments for patients with cancer and other non-oncology diseases.

Merck's Keytruda Fails to Meet Goal in Breast Cancer Trial

Merck's Keytruda Fails to Meet Goal in Breast Cancer Trial

Merck says one of its key cancer-fighting drugs, Keytruda, failed to meet its stand-alone goal of treating an aggressive type of breast cancer.

Http://www.merck.com

Http://www.merck.com

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Peloton Therapeutics, Inc.

Merck Provides Update On Phase 3 KEYNOTE-119 Study Of KEYTRUDA® (pembrolizumab) Monotherapy In Previously-Treated Patients With Metastatic Triple-Negative Breast Cancer

Merck Provides Update On Phase 3 KEYNOTE-119 Study Of KEYTRUDA® (pembrolizumab) Monotherapy In Previously-Treated Patients With Metastatic Triple-Negative Breast Cancer

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Phase 3 KEYNOTE-119 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, as monotherapy for the second- or third-line treatment of patients with metastatic...

Rally or Selloff?: Cramer's 'Mad Money' Recap (Friday 5/17/19)

Rally or Selloff?: Cramer's 'Mad Money' Recap (Friday 5/17/19)

Jim Cramer says we'll need to pay close attention to retailers' earnings. Here's your game plan for next week.

TheStreet Quant Rating: A- (Buy)